SYX3759 / SynRx Therap - LARVOL DELTA

Pre-clinical study of SYX3759, a novel PARG inhibitor for the treatment of homologous recombination deficient malignancies (AACR 2023) - "Compared to PARPi, such as Olaparib, SYX3759 shows selective and potent cytotoxicity on a broader spectrum of homologous recombination deficient (HRD) tumors both in vitro and in vivo. Moreover, SYX3759 is well tolerated at the highest dose tested without obvious adverse effect on hematopoiesis. Collectively, SYX3759 is a potent PARG inhibitor both in vitro and in vivo warranting future clinical trials for the treatment of HRD cancers and beyond."

Preclinical • Oncology • BRCA • HRD • XRCC1